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G
laucoma will affect approximately
79.6 million people worldwide by
2020.1 Although there are a variety
of nonsurgical treatment options, one of the
biggest barriers to treatment success is pa-
tient compliance.2 Recent advances in the
design of biomaterials aim to improve drug
delivery by controlling the timing and loca-
tion of drug release.36 These advances are
being adapted to ocular drug delivery sys-
tems that may improve patient adherence
through the use of therapeutic contact
lenses.79 Unlike eye drops and drug-soaked
lenses, which show burst release profiles,
novel contact lensesmade throughmolecular
imprintingor embeddedmicroparticlesmain-
tain a local therapeutic dosage for a longer
time.1013 Utilizing these types of therapeutic
contact lenses would lead to lower required
dosage and less frequent drug application,
thereby improving patient adherence.
A clinically effective drug delivery
system must also address the challenges
of commercial manufacturing and distribu-
tion. Most soft contact lenses, made of poly-
2-hydroxyethyl methacrylate (polyHEMA),
must be shipped and stored wet to avoid
becoming brittle. However, this can cause
drug-loaded contact lenses to elute drugs
prematurely, rendering the drug delivery sys-
tem ineffective. This has necessitated the
development of smarter delivery systems,
which release their therapeutic payloadunder
artificial or biological stimuli.1417 One poten-
tial biological stimulus is lysozyme, anenzyme
in lacrimal fluid capable of catalyzing the
hydrolysis of 1,4-β-glycosidic bonds in pepti-
doglycans and chitodextrins.18 The goal of
this work is to develop a lysozyme-triggered
drug delivery system capable of delivering a
drug in a controlled fashion.
Recently, nanomaterials have mediated
marked advances in biomedical imaging
and drug delivery.1927 In particular, nano-
particles are effective vehicles for ocular
delivery of bioactive molecules, such as
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ABSTRACT Temporarily implanted devices, such as drug-loaded con-
tact lenses, are emerging as the preferred treatment method for ocular
diseases like glaucoma. Localizing the delivery of glaucoma drugs, such as
timolol maleate (TM), can minimize adverse effects caused by systemic
administration. Although eye drops and drug-soaked lenses allow for local
treatment, their utility is limited by burst release and a lack of sustained
therapeutic delivery. Additionally, wet transportation and storage of drug-
soaked lenses result in drug loss due to elution from the lenses. Here we present a nanodiamond (ND)-embedded contact lens capable of lysozyme-
triggered release of TM for sustained therapy. We find that ND-embedded lenses composed of enzyme-cleavable polymers allow for controlled and
sustained release of TM in the presence of lysozyme. Retention of drug activity is verified in primary human trabecular meshwork cells. These results
demonstrate the translational potential of an ND-embedded lens capable of drug sequestration and enzyme activation.
KEYWORDS: nanomedicine . contact lens . nanodiamond . drug delivery . biomaterials
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small molecule therapeutics and nucleic acids.28
Uniquely faceted detonation nanodiamond (ND) par-
ticles have been utilized for numerous applications
in biomedical imaging, sensing and therapeutic
delivery.2932 The uniquely faceted surface architec-
ture of NDs enables particle dispersal, coordinates
water molecules around the surface, and allows potent
and reversible drug binding. These mechanisms have
mediated marked improvements to applications such
as drug delivery and biomedical imaging in multiple
models.31,3335 In addition to being highly effective
nanocarriers, ND biocompatibility has been observed
in many in vitro and in vivo studies.31,33,36 Comparing
controls and mice treated with high doses of NDs or
NDs carrying chemotherapeutics, there are no signifi-
cant differences in hematological or serum markers of
inflammation and toxicity.33 Additionally, histological
analysis of the kidney, liver and spleen found no
differences between NDs and PBS controls.31 Although
the ocular compatibility of NDs has not been evalu-
ated, carbon nanohorns, a related and similarly sized
material, do not induce any clinical abnormalities on
eye irritation tests in rabbits.37
Nanodiamonds have previously been incorporated
into polymer matrices to improve mechanical proper-
ties and/or elute therapeutic compounds.3840 In ad-
dition, previous reports have demonstrated the ability
to create and utilize optically transparent ND films.41
These developments support the fabrication of an
ND-based contact lens for controlled delivery of ocular
therapeutics. In the design presented in this work,
individual NDs are coated with polyethyleneimine
(PEI) and then cross-linked with an enzyme-cleavable
polysaccharide, chitosan, forming a ND-nanogel load-
ed with timolol maleate (TM) (Figure 1a). These
ND-nanogels are then embedded within a polyHEMA
matrix and cast into contact lenses (Figure 1b).
RESULTS AND DISCUSSION
ND-Nanogel Synthesis and Characterization. For optimal
contact lens fabrication and to ensure clinical-grade
optical clarity, the NDs must be well dispersed in the
gel matrix. Electrostatic and covalent interactions,
which are mediated by surface graphitic carbon, cause
primary diamond particles (∼5 nm) to spontaneously
form clusters of up to 200 nm. The graphitic carbon can
be eliminated by oxidation in air at 420 C.42,43 In
addition, this method improves the homogeneity of
the surface chemical groups, converting them into
carboxylic acids and cyclic acid anhydrides.44 Fourier
Transform Infrared (FTIR) spectra of the heat-treated
NDs shows a CdO stretching peak from carboxylic
acid at 1775 cm1, indicating successful oxidation
(Figure 2a). ζ-potential measurement shows a shift
from an average of þ36.8 mV for the pristine NDs to
40.7 mV for the air oxidized NDs due to surface
carboxylic acid groups (Figure 2b). The air oxidized
NDs, which form a stable colloidal solution, have an
Figure 1. Schematic illustration of our lysozyme-activated drug eluting contact lens. (a) Drug-loaded ND-nanogels are
synthesized by cross-linking PEI-coated NDs and partially N-acetylated chitosan (MW = 57 kDa; degree of N-acetylation =
50%) in the presence of timololmaleate. TheND-nanogels are then embedded in a hydrogel and cast into enzyme-responsive
contact lenses. (b) Exposure to lacrimal fluid lysozyme cleaves the N-acetylated chitosan, degrading the ND-nanogels and
releasing the entrapped timolol maleate while leaving the lens intact.
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average particle size of 32.2 nm on dynamic light
scattering (DLS) (Figure 2b).
To increase the surface density and accessibility
of reactive groups, the oxidized NDs are then coat-
ed with highly branched PEI-800 using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) and
N-hydroxysuccinimide (NHS). FTIR of the ND-PEI is
indicative of covalent attachment of ND-surface car-
boxylic acids to amines on the PEI, showing peaks
at 3380, 2950, 2825, 1640, and 1560 cm1 (Figure 2a).
Compared to oxidized NDs, ND-PEI show a slight
increase in size (∼6 nm) and a change in the average
ζ-potential to þ39.4 mV (Figure 2b). Furthermore,
comparing the TEM images of pristine NDs and ND-
PEI shows that ND-PEI particles are larger, smoother
and more electron-dense than the pristine particles
(Figure 2c,d). This work presents a novel method for
dispersion and stabilization of reactive NDs in water,
facilitating the biological or chemical functionalization
of NDs.
The next step in the production of the ND-em-
bedded contact lens is the synthesis of the ND-nano-
gels by cross-linking ND-PEI clusters with N-acetylated
chitosan to form a lysozyme degradable nanogel.
Chitosan is a linear polysaccharide composed of
D-glucosamine and N-acetyl-D-glucosamine coupled
with 1,4-β-glycosidic bonds that can be cleaved by
lysozyme. The rate at which chitosan is degraded by
lysozyme is dependent on the degree of acetylation
(DA), with increased acetylation associated with more
rapid degradation.45 Prior to coupling to ND-PEI, chit-
osan is acetylated to 50%DA (elemental analysis) using
acetic acid according to the protocol by Ren et al.45
(Supporting Information Figure S1). ND-PEI is first
modified with succinic anhydride and then coupled
to acetylated chitosan using EDC/NHS in the presence
of TM. This generates the drug-encapsulated, enzyme-
cleavable ND-nanogels. Although the chitosan could
have been directly coupled to the ND surface, the PEI
layer allows for more effective lysozyme cleavage and
TM release. FTIR analysis of the ND-nanogel demon-
strates the characteristic peaks for amide bonds and
amines, which is consistent with the presence of
chitosan and PEI (Figure 2a). For the ND-nanogels,
the peaks for amide bonds and primary amine groups
from chitosan cannot be distinguished because they
overlap with the characteristic peaks of PEI. The en-
trapment of drug is confirmed by the presence of
characteristic peaks for TM at 2967, 2853, 1705, and
1375 cm1 (Figure 2a). In addition, DLS data demon-
strates that theND-nanogels have an average diameter
of 106.5 nm (Figure 2b), which is consistent with TEM
images showing that each nanogel is a network of
individual NDs (Figure 2e).
Figure 2. Characterization of ND-nanogel during synthesis. (a) FT-IR spectra of (1) pristine ND, (2) oxidized ND, (3) ND-PEI, (4)
N-acetylated chitosan, (5) ND-nanogel, (6) timolol [TM]-loadedND-nanogel, and (7) timolol. (b) Particle size (red-colored bars)
and ζ-potential (blue-coloredbars) distributions of (1) pristineND, (2) oxidizedND, (3) ND-PEI, and (4) TM-loadedND-nanogel.
TEM images of (c) pristine ND, (d) ND-PEI, and (e) TM-loaded ND-nanogel.
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Contact Lens Synthesis and Characterization. To serve
as an effective ocular drug delivery platform, the ND-
nanogels are incorporated into a polyHEMA matrix
and cast into contact lenses (Figure 3a). Briefly,
the drug-loaded ND-nanogels were dispersed by ultra-
sonication in a solution of HEMA before adding
methacrylic acid (5% v/v), ethylene glycol dimethacry-
late (0.25% v/v) and a photoinitiator (Darocur, 0.2% v/v).
This composition is commonly used to make soft con-
tact lenses and has an average pore size of 34.7 Å,43
which is suitable for lysozyme (30  30  45 Å)
penetration. In addition to porosity, the optical clarity
and water content of polyHEMA gels make them ideal
for soft contact lenses. The addition of the ND-nano-
gels to polyHEMA does not induce any visible altera-
tions in the lens optical characteristics (Figure 3b). The
polyHEMA contact lens shows an average transmission
of 93.8% prior to ND-nanogel loading. The addition of
0.1% pristine ND, 0.1% ND-nanogel or 0.2% ND-
nanogel does not lower this average transmission
by more than 10% (Figure 3c). The 0.2% ND-nanogel
shows a transmittance of 84.5%.
Another important parameter in the design of
therapeutic contact lenses is water content. In addition
to affecting lysozyme penetration and drug elution,
water content dictates the oxygen permeability of the
lens. Adding ND-nanogels, pristine NDs or PEI-chitosan
causes little impact on the water content of the lens,
with values ranging from 63.3% to 64.5% (Figure 3c).
Additionally, scanning electron microscopy (SEM)
shows that the surfaces of polyHEMA and ND-nanogel
embedded lenses are similar (Supporting Information
Figure S2). The only observable difference between the
two lenses is the presence of approximately 100 nm
ND-nanogels on the drug eluting lens surface. Given
that the additives comprise only 0.1% (w/w) of the total
Figure 3. Characterization of physical properties of contact lenses. (a) ND-nanogels can be embedded into polyHEMA gels
and cast into contact lenses. (b) ND-nanogel embedded lenses maintain optical transparency. (c) Comparison of average
visible light transmittance (400700 nm) and water content of polyHEMA lenses without additives, with 0.1% (w/w) PEI-
chitosan, with 0.1% (w/w) pristine ND, with 0.1% (w/w) ND-nanogel or 0.2% (w/w) ND-nanogel. (d) Tensile stressstrain
curves comparing polyHEMA lenses without additives, with 0.1% (w/w) PEI-chitosan, with 0.1% (w/w) pristine ND, with 0.1%
(w/w)ND-nanogel or 0.2% (w/w)ND-nanogel. (e) Young'smodulus of thepolyHEMA lenseswithout additives,with 0.1% (w/w)
PEI-chitosan, with 0.1% (w/w) pristine ND, with 0.1% (w/w) ND-nanogel or 0.2% (w/w) ND-nanogel, as determined by the first
5% of the stressstrain curve slope.
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lens mass, it is expected that the bulk characteristics of
the gel would remain largely unchanged.
As contact lenses are subjected to innumerable
mechanical stresses during the course of insertion,
use and removal, themechanical properties of the lens
matrix are important design considerations. Previous
reports on polymermatrices with embeddedNDs have
demonstrated an enhancement in mechanical proper-
ties with the addition of a small amount of diamond.29
Tensile testing of the contact lenses demonstrates that
the addition of 0.1% (w/w) pristine NDs to the poly-
HEMA lens boosts the Young's modulus by 31%
(Figure 3d,e). The contact lenses containing the drug-
loadedND-nanogels (0.1 and 0.2%w/w) show4050%
improvement in Young's modulus up to approximately
0.2 MPa. In contrast, the control lenses containing PEI-
Chitosan (0.1% w/w) show no alteration in mechanical
properties. Combined, these results indicate that the
incorporation of ND particles into the contact lens
reinforces the polymer matrix, improving tensile
strength and boosting elastic modulus. At 0.2 MPa,
the ND-embedded hydrogels are still less stiff than
commercial polyHEMA lenses (∼0.5 MPa). The lack of
professional lens fabrication equipment may explain
this discrepancy. Nevertheless, NDs make an attractive
lens nanofiller due to their ability to improve tensile
strength without altering overall lens thickness. Soft
contact lens design is a challenging balancing act
between lens mechanical strength and oxygen diffu-
sion. Thicker lenses are stronger but they limit the
amount of oxygen that reaches the cornea. By incor-
porating NDs into the lens matrix, more durable lenses
could be producedwithout sacrificing lens thickness or
user comfort.
Enzyme-Triggered Drug Delivery. While the ND-nano-
gels improve matrix mechanical properties, the end
goal of these studies is to produce a contact lens that
releases TM in a controlled manner. To this end, the
elution of TM was studied in three different types of
contact lenses: ND-nanogel lenses, TM-soaked lenses
and molecularly imprinted lenses.9 TM released from
contact lenses was first purified by HPLC and then
quantified using its absorbance in the visible range.
Both the drug-soaked and molecularly imprinted con-
tact lenses show almost complete release of TM within
the first hour (Figure 4). In contrast, in the absence of
lysozyme, TM release from the ND-nanogel lens is
undetectable. After treatment with lysozyme, the
cumulative drug release from the ND-nanogel lens is
9.41 μg over 24 h (Figure 4). Some variability in the TM
release profile, including some burst release, is ob-
served after 48 h of lysozyme treatment. This is likely
due to variation in the size and depth of ND-nanogels
within the polymer matrix and could likely be elimi-
nated with minimal optimization and the utilization of
commercial-grade lens fabrication equipment. How-
ever, the behavior after 48 h is less concerning because
therapeutic lenses are commonly worn for a 24-h
period. Additionally, TM release is not associated with
ND release from the lens, as determined by tracking
fluorescently labeled ND-PEI (Supporting Information
Figure S3). Although NDs have previously been shown
to be biocompatible, the stable retention of NDs is an
additional safety assurance to users.
For the ND-nanogel lens to find clinical utility, it
must be able to elute a sufficient amount of drug over
24 h. The recommended starting dosage of TM is
2 drops of 0.25% solution per day. Assuming a typical
eye drop volume of 25 μL and bioavailability of 1%, the
total dosage would be 1.7 μg/day.46 Because the
thickness of the lenses generated here are 7-times as
thick as a standard contact lens (700 μm vs 100 μm) the
amount of drug released must be scaled. Taking the
fractional mass released as inversely proportional to
the square of the lens thickness, the commercial ver-
sion of the ND-nanogel lens will release about 0.192
μg/day or 11.3% of the standard dosage. However, a
recent pharmacodynamics study using dogs showed
that drug-soaked lenses releasing 20% of the standard
eye drop dosage are capable of achieving the same
efficacy as the eye drops.47 Hence, further optimization
of the ND-nanogel lens would produce a clinically
relevant and commercially viable product.
Biological Activity of Released Drug. To produce a func-
tional drug delivery system, the TM released from the
lens must retain its activity. Confirmation of the biolo-
gical activity of TM is determined based on its antiox-
idant capacity.48 Pretreatment of primary human
trabecular meshwork cells with TM will protect cells
against oxidative stress induced by hydrogen perox-
ide. The heterogeneous nature of primary cells serves
as suitable test bed for ND-lens efficacy. Cell viability is
assessed using two separate assays  absorbance-
based XTT, which measures mitochondrial enzyme
Figure 4. Enzyme-triggered drug release. Drug-eluting pro-
files from drug-soaked (black line), molecularly imprinted
(red line) and ND nanogel-embedded contact lenses (blue
line) in saline solution at 37 C as determined by HPLC
analysis of TM. Lysozyme (2.7 mg/mL) in PBS was added
after 24 h of incubation (N = 3 for each type of lens).
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activity, and fluorescence-based CellTiter-Blue, which
measures mitochondrial, cytoplasmic and microsomal
enzyme activity. Cells pretreated with TM eluted from
the ND-nanogel embedded contact lens (1 μg/mL) or a
standard solution of TM (1 μg/mL) prior to the addition
of hydrogen peroxide show improved viability using
both the XTT (Figure 5a, p < 0.005) and CellTiter-Blue
(Figure 5b, p < 0.0005) assays. Importantly, there is no
difference in cell viability between the standard and
lens-eluted TM.
CONCLUSION
These studies have demonstrated that the ND-na-
nogel embedded contact lens serves as an effective
device for the enzyme-triggered delivery of timolol
(TM). The ND-nanogels sequester TM prior to lysozyme
activation and subsequently allow sustained drug
release. This eliminates the uncontrolled release ob-
served with other lens types, thus facilitating large-
scale manufacturing, storage and distribution. As a
nanofiller, ND also improves themechanical properties
of our lens. Optical clarity, water content and oxygen
permeability are maintained at practical levels. Most
importantly, eluted TM from our ND-nanogel lens
retains drug activity as verified by an in vitro model.
In addition, this work has provided a newmethod for
generating a stable, aqueous colloid of reactive NDs
through the covalent conjugation of PEI. ND-PEI can
be readily functionalized using aqueous chemistry,
making it ideal for reactions where organic solvents
cannot be used.
The system developed here, based on NDs, provides
a new platform for the development of hydrogels
capable of enzyme-triggered drug release. The contact
lens device is capable of mediating therapeutic elution
from the ND-nanogel via lysozyme-dependent poly-
saccharide degradation. Since drug loading is achieved
by entrapment, therapeutics other than TM can be
easily incorporated for lysozyme-triggered delivery for
the eye and other regions. Furthermore, the same
approach can be applied to other biological systems
by replacing chitosan with a different enzyme-cleava-
ble polysaccharide. This polysaccharide can be con-
jugated to the ND surface via similar facile synthesis
method. By utilizing NDs in this novel approach to
enzyme-triggered drug delivery, we are able to achieve
enhanced mechanical performance in addition to ef-
fective drug delivery. Notably, nanodiamonds, which
are byproducts of existing mining and refining opera-
tions, can be processed into uniform particles with
truncated octahedral structures using straightforward
methodologies like ball milling, acid washing, and
ultrasonication. Therefore, their availability and scal-
ability make them favorable materials for the synthesis
of therapeutic contact lenses and other drug-eluting
materials.
MATERIALS AND METHODS
Preparation and Characterization of Timolol-Loaded ND-Nanogel.
N-Acetylation of chitosan (Chitosan-10, degree of acetylation
(DA) 15%, MW = 57 kDa, Wako Pure Chemical Industries Ltd.)
was performed as previously described.45 Chitosan was first
dissolved in 3% (v/v) acetic acid solution before the addition of
methanol. Acetic anhydride was added to this solution, stirred
at room temperature overnight and then neutralized with
1 mol/L NaOH to yield a white precipitate. The collected
precipitate was washed with water in wash/centrifugation
cycles and lyophilized to give a white powder. The degree of
N-acetylation (DA) of chitosan was calculated from elemental
analysis.
Freeze-dried pristine NDs were air oxidized at 420 C for
2.5 h. The NDs were then dissolved in anhydrous DMSO and
ultrasonicated for 30 min. EDC (Sigma) and NHS (Sigma) were
added to the oxidized NDs in DMSO. After stirring for 1 h, excess
Figure 5. Evaluation of the antioxidant capacity of TM using primary human trabecular meshwork cells. Cells were treated
with control, standard TM (1 μg/mL) or ND-nanogel-eluted TM (1 μg/mL) prior to incubation with 20 μM H2O2 to induce
oxidative cell death. (a) XTT cell viability assay (N = 8; *p = 4.2  108, **p = 6.0 105). (b) CellTiter-Blue cell viability assay
(N = 6; *p = 0.033, **p = 1.0  106, ***p = 3.3  105, ****p = 0.0024).
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polyethylenimine (PEI, MW = 800, Sigma) was added to the
solution and it stirred overnight. The product was washed with
water in consecutive washing/centrifugation cycles. ND-PEIs
were conjugated with excess succinic acid to yield carboxylated
ND-PEIs. Amide cross-linking reaction was performed between
N-acetylated chitosan and NHS-activated ND-PEI in the pre-
sence of timolol, yielding timolol-loaded ND-nanogel. All func-
tionalized NDs were confirmed by FTIR (Nexus 870 spec-
trometer (Thermo Nicolet)). TEM images were taken using a
200 kV JEOL JEM-2100F TEM. Hydrodynamic size and ζ-poten-
tial measurements were performed using Zetasizer Nano ZS
(Malvern Instruments, Malvern, U.K.) with NDs in deionized
water at 50 μg/mL.
Preparation of ND-Embedded Contact Lenses. The contact lenses
were prepared by free-radical copolymerization. ND-nanogels
were suspended in 2-hydroxyethyl methacrylate (HEMA, Sigma)
solution before the addition of methacrylic acid (MAA, 5% v/v,
Sigma), ethylene glycol dimethacrylate (EGDMA, 0.25% v/v,
Sigma) and 2-hydroxy-2-methylpropiophenone (Darocur
photoinitiator, 0.2% v/v, Sigma). The monomer solution was
poured into an aluminum mold with 0.50 mm center thickness.
Polymerization was initiated with UV irradiation (6.5 mW/cm2 at
365 nm). The gel was soaked in deionizedwater for 4 h and discs
(12 mm diameter) were punched out with a cork borer. The
lenses were then immersed in 0.9% NaCl solution for 2 days to
remove unreacted monomers and initiator. Molecularly im-
printed contact lenses and drug-soaked lenses were manufac-
tured as previously described.9 Drug loading was done by
soaking in 0.02 mM of timolol solution for 3 days.
Characterization of Contact Lenses. NDswere imaged on a 200 kV
JEOL JEM-2100F TEM. NDs (5 μg/mL) in deionized water were
pipetted onto lacey carbon on copper TEM grids (Ted Pella, Inc.,
Redding, CA) and the solvent was removed after deposition for
3 min. SEM images were obtained using a Hitachi S-4800-II.
Samples were lyophilized before being coated twice with 5 nm
thick OsO4 using an osmium plasma coater (Structure Probe,
Inc.). Rectangular specimens were placed on Instron 5533 and
tested with three 10% length preload cycle stretches before an
ultimate strength test. The modulus of elasticity of each lens
was calculated by using the initial 5% slope from the stress
strain graph. Thewater content of contact lenses was calculated
by the ratio of the weight of water in the hydrogel to the total
weight of the hydrogel.
Determining Timolol-Release Profiles. The release of timolol at
37.8 C from hydrogels was measured in triplicates over 72 h in
5 mL of saline or artificial lacrimal fluid (6.78 g/L NaCl, 2.18 g/L
NaHCO3, 1.38 g/L KCl, 0.084 g/L CaCl2, pH 7.2). Timolol-release
profile was carried out using a Varian high performance liquid
chromatography (HPLC) (Milford, MA). A mixture of 0.1 M PBS
(pH 2.8)/methanol (40:60) delivered at 1.0 mL/min was used as
the mobile phase. The peak area at 295 nm was used for
calculation.
Culturing of Human Trabecular Meshwork Cells (HTM). Primary HTM
cells (P10879, Innoprot) were propagated in fibroblast growth
medium-2 (CC-3132 Lonza) with the provided supplement kit
and 1% (v/v) penicillinstreptomycin. Cells were maintained in
a humidified incubator (37 C, 5% CO2). At 80% confluence, the
cells were trypsinized for subculturing or for experiment. After 4
days of lysozyme addition to the hydrogel, the eluate, which
contained timolol, was used for the experiments.
Determination of Cell Viability via XTT Assay. The eluate was
diluted to a timolol concentration of 1 μg/mL before being
applied to the HTM cells (P5) for 10 min. Hydrogen peroxide
(0.2 μM) was then applied for 15 min. The XTT media was pre-
pared by adding 1.5 mL of XTT (Invitrogen) solution (1 mg/mL
XTT in PBS) and 6.46 μL of menadione (Enzo Life Sciences,
10 mg/mL ethanol) to 8.5 mL of media. For the assay, 50 μL of
XTTmedia was added to 100 μL of fresh media in each well. PBS
washing was done once in between these steps. The plate was
incubated for 2 h at 37 C, shaken and read at 450 nm with a
spectrophotometer. Cell viability was expressed as a percent-
age of the control wells.
Determination of Cell viability via CellTiter-Blue Assay. The eluate
was diluted to a timolol concentration of 1 μg/mL before being
applied to the HTM cells (P4) for 10 min. Hydrogen peroxide
(20 μM)was then applied for 30min. A volumeof 20 μL CellTiter-
Blue (Promega) was then added to each well containing 100 μL
of media. The plate was incubated for 2 h at 37 C and read at
560 nm/590 nm (emission/excitation). Cell viability is expressed
as a percentage of the control wells.
Statistical Methods. All statistics were performed in Microsoft
Excel. All p-valueswere obtained using two-tailed students t test
with a minimum of 6 replicates.
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